Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.74 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.74 |
| ▸ | BCR | P11274 | 2/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.74 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.74 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.74 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.74 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.74 |
| ▸ | LCK | P06239 | 2/20 | 0.74 |
| ▸ | SRC | P12931 | 2/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.74 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.74 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.74 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.74 |
| ▸ | GAK | O14976 | 1/20 | 0.74 |
| ▸ | MLNR | O43193 | 1/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011304 | 0.95 | ABL1 (1.00) | ABL1ABL2KCNH2CYP3A4DDR2 | |
| SCHEMBL24122640 | 0.95 | ABL1 (1.00) | ABL1ABL2KCNH2CYP3A4DDR2 | |
| SCHEMBL21367370 | 0.91 | ABL1 (0.85) | ABL1ABL2KCNH2CYP3A4DDR2 | |
| SCHEMBL13194694 | 0.89 | ABL1 (0.88) | ABL1ABL2KCNH2CYP3A4DDR2 | |
| SCHEMBL12989619 | 0.89 | ABL1 (1.00) | ABL1ABL2KCNH2CYP3A4DDR2 | |
| SCHEMBL589689 | 0.89 | ABL1 (1.00) | ABL1ABL2KCNH2CYP3A4DDR2 | |
| SCHEMBL16644576 | 0.88 | ABL1 (0.82) | ABL1ABL2KCNH2CYP3A4DDR2 | |
| SCHEMBL15242137 | 0.88 | ABL1 (0.85) | ABL1ABL2KCNH2CYP3A4DDR2 | |
| SCHEMBL591027 | 0.87 | ABL1 (1.00) | ABL1ABL2KCNH2CYP3A4DDR2 | |
| SCHEMBL15473029 | 0.87 | ABL1 (0.83) | ABL1ABL2KCNH2CYP3A4DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022225972-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20210393628-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | SMN1; SMN2, MCL1, NLN | ABL1 76/4885ABL2 424/4885KCNH2 2222/4885 |
| US-20210393628-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | CD4, ICOS, NFATC1 | ABL1 237/4885ABL2 620/4885KCNH2 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.